TECH vs. MRNA

In the year-to-date period, TECH achieves a -32.62% return, which is significantly higher than MRNA's -36.12% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Bio-Techne Corporation (TECH) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current TECH Sharpe Ratio is -0.92, which is comparable to the MRNA Sharpe Ratio of -1.21. The chart below compares the historical Sharpe Ratios of TECH and MRNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

TECH's dividend yield for the trailing twelve months is around 0.66%, while MRNA has not paid dividends to shareholders.

The maximum TECH drawdown since its inception was -74.39%, smaller than the maximum MRNA drawdown of -95.12%. Use the drawdown chart below to compare losses from any high point for TECH and MRNA.

The current volatility for Bio-Techne Corporation (TECH) is 15.54%, while Moderna, Inc. (MRNA) has a volatility of 22.45%. This indicates that TECH experiences smaller price fluctuations and is considered to be less risky than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Bio-Techne Corporation and Moderna, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.